Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility (CS-EOSP-ICSI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04071574

Recruitment Status : Recruiting

First Posted : August 28, 2019

Last Update Posted : August 28, 2019

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Nehman Makdissy, Lebanese University

Study Description

Brief Summary:

The study will describe the effectiveness of ovarian stimulation in correlation with female infertility causes in a Lebanese population: a comparative study using 5 protocols of ovulation induction (treatment with "A" gonadotropins alone, "B" short GnRH agonist, "C" multiple-dose GnRH antagonist, "D" long GnRH agonist and "E" combined protocol of GnRH antagonist and agonist) and the outcomes of ICSI. This comparative study will help clinicians to select the relevant protocol of ovarian stimulation related to the female infertility disorders.

Condition or disease	Intervention/treatment	Phase
Female Infertility Female Infertility Due to Ovulatory Disorder Premature Ovarian Failure Polycystic Ovary Syndrome Female Infertility of Tubal Origin Ectopic Pregnancy Salpingitis Female Infertility Due to Tubal Block Female Infertility Due to Tubal Occlusion Hydrosalpinx Female Infertility - Cervical/Vaginal Female Infertility Endocrine Endometriosis Fibroids Congenital Uterine Anomaly Infections Uterine Female Infertility of Other Origin	Drug: Human Chorionic Gonadotropin (hCG) Drug: Gonadotropins Drug: GNRH-A Triptorelin Drug: GnRH antagonist	Not Applicable

Show detailed description

Detailed Description:

One in six couples worldwide is affected by infertility, which defined as the inability to conceive after one year or more of regular and unprotected intercourse. It has been stated that 48.5 million couples in the world, with unprotected coitus, suffer from infertility. In about 50% of them, the infertility is due to female factors and diseases associated with the female reproductive system. Epidemiological studies show that 10 to 15% of all married couples are estimated to have infertility problems in the Middle East. Lebanon, in particular, is characterized with traditional and westernized lifestyles; It has high rates of smoking and caffeine intake, pollution and high rates of consanguinity marriage (11 to 17%), which affect considerably the conception rate.

The desire to procreate is naturally present in women all over the world. Due to various advances in medical procreation techniques, it has become possible for many women to realize their hope. Women were more likely to be psychologically distressed to infertility and suffer from poor quality of life more than men once they are diagnosed as infertile.

The causes of female infertility can have a genetic, anatomical or physiological origin. Among the most common genetic causes of female infertility are the chromosomes abnormalities: the numbers of X chromosomes, homogeneous or mosaic; other abnormalities are reciprocal translocations, Robertsonian translocations, inversions, supernumerary markers or abnormalities of the X chromosome structure. In such cases, no treatment and procreation require an egg donation. But the main causes of female infertility are physiological and anatomical, such as ovulatory disorders (25%), endometriosis (15%), pelvic adhesions (12%), tubal blockage (11%), other tubal abnormalities (11%), hyperprolactinemia (7%) and some minor causes. In addition, leiomyomas, fibroma, polyps, and tubal disease, may reduce fertility. In addition came the environmental factors (drugs, pesticides, food, tobacco ...) and there is an increase in the percentage of infertile women with advancing female age. A French national survey on lifestyles and toxic factors in infertile couples showed that in women, tobacco generates a risk twice as high as being infertile, a decrease in the ovarian reserve where the level of anti-Mullerian hormone (AMH) decreases, irregular short cycles and dysmenorrhea are also found in smokers. In addition, products contained in tobacco such as cotinine, cadmium and hydrogen peroxide are found in the follicular fluid and would be responsible for an alteration of the recovery of oocyte meiosis.

Couples who have problems with conception are referred to a medically assisted procreation (MAP) for fertility treatments. These treatments can be very stressful both psychologically and physically. Indeed, the numerous medical appointments and examinations, as well as the many bereavements and failures, experienced following repeated attempts at conception can to consume the married, social and professional life of couples. In addition, fertility issues require significant financial resources to cover the costs of fertility treatments, but also those related to the maternal and fetal complications of pregnancy, which are more frequent in the case of MAP pregnancies than in spontaneous conception.

Control of the ovarian stimulation is the key component of assisted reproductive technologies (ART) that have shifted the clinical practice of natural mono-follicular cycles into multi-follicular stimulated cycles. The increase in the number of follicles, and consequently the number of oocytes recovered, improved pregnancy rates in women undergoing In Vitro Fertilization (IVF) / Intra-Cytoplasmic Sperm Injection (ICSI), not only by increasing the number of available embryos but also by allowing embryo culture extended and allowing the selection of higher quality embryos to be transferred. However, several studies have addressed the issue of the optimal number of oocytes recovered following controlled ovarian stimulation (COS) for IVF / ICSI and demonstrated that the ovarian response is independently related to Live Birth Rate (LBR) after IVF / ICSI.

Many new treatment modalities for ovarian stimulation have been introduced over the years - often with insufficient evidence of safety and efficacy - using different compounds and regimens for ovarian stimulation, triggering oocyte maturation, interventions preceding stimulation supplementation phase. The most important clinical challenge is to find the right balance between improving the chances of success (birth of a healthy child), a reasonable cost, acceptable discomfort for the patient, and a minimal complication rate. New developments make ovarian stimulation less intense and more individualized. The choice of the ovarian stimulation protocol is one of the most important steps in IVF/ICSI treatment.

This study aims to identify and evaluate ovarian stimulation protocols applied to different patients with different causes of female infertility prior to medically assisted procreation techniques in order to know if there is a relationship between a given protocol and the result obtained for each class of infertility. Therefore, 360 ICSI in 200-300 couples will be studied in order to evaluate the link between ovarian stimulation protocols and outcomes of ICSI.

The population will be divided into 3 groups:

Group "OD" for ovulation disorders caused by endocrine disorders such as the polycystic ovarian syndrome (PCOS) and/or premature ovarian failure (POF)
Group "TD" for tubal disorders caused by previous ectopic pregnancy, salpingectomy, tubal obstruction and/or hydrosalpinx
Group "UCD" for uterine and cervical disorders caused by fibroids, endometriosis, infection and/or congenital uterine anomaly (CUA)

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	200 participants
Allocation:	Non-Randomized
Intervention Model:	Parallel Assignment
Intervention Model Description:	comparative protocols
Masking:	None (Open Label)
Primary Purpose:	Health Services Research
Official Title:	Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Women With Infertility Problems
Actual Study Start Date :	February 1, 2018
Actual Primary Completion Date :	August 22, 2019
Estimated Study Completion Date :	December 30, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Female Infertility Infertility

Genetic and Rare Diseases Information Center resources: Ectopic Pregnancy

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: Protocol "A" Protocol with gonadotropins alone without agonist or antagonist: Gonadotropin treatment begins after spontaneous menses. The gonadotropins (e.g. Menopur, 150-225IU) are injected daily from D2/3 of the cycle (Gonadotropin dose varies based on the follicular response). The moment to trigger ovulation by administration of HCG (e.g. Ovitrelle or Pregnyl, 10.000IU) is determined by monitoring ovulation (folliculogenesis) approximately 14 days after gonadotropins regimen and the presence of at least 3 follicles with 18 mm sizes and at least the levels of E2 reaches 250-300 pg/ml. 36 h after HCG triggering, the mature oocytes are retrieved.	Drug: Human Chorionic Gonadotropin (hCG) Administration of hCG (10.000IU) for ovulation triggering Other Name: OVITRELLE / PREGNYL Drug: Gonadotropins Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day) Other Name: MENOPUR
Active Comparator: Protocol "B" Short GnRH agonist protocol: For the short GnRH agonist protocol, the administration of gonadotropins begins at the same time as that of the agonist, which makes it possible to take advantage of the action of endogenous gonadotropins released by the flare-up effect of the agonist. A low dose of GnRH agonist (e.g., triptorelin (Decapeptyl 0.1mg/day)) is administered in parallel to gonadotropin (e.g. Menopur, 150-225 IU) daily starting on cycle-day 2 (Gonadotropin dose varies based on the follicular development). Continual administration of GnRH agonist and gonadotropin lasts until HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU), ~14 days post GnRH agonist regimen when follicles size reached 16-18 mm and at least the levels of E2 reaches 250-300 pg/ml. 36 h after HCG triggering, the mature oocytes are retrieved.	Drug: Human Chorionic Gonadotropin (hCG) Administration of hCG (10.000IU) for ovulation triggering Other Name: OVITRELLE / PREGNYL Drug: Gonadotropins Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day) Other Name: MENOPUR Drug: GNRH-A Triptorelin Administration of Triptorelin (0.1mg/day) Other Name: DECAPEPTYL
Active Comparator: Protocol "C" Multiple-dose antagonist protocol: For the GnRH antagonist protocol, a low dose of GnRH antagonist (0.25 mg/day) is administered. The protocol starts with the administration of gonadotropin (e.g. Menopur, 150-225 IU) daily which is initiated after monitoring of patients' follicles sizes on cycle-day 2/3 (Gonadotropin dose varies based on the follicular response). Almost after the 6th days of gonadotropin injection or when follicular size reaches more than or equal to 14 mm, GnRH antagonist (e.g., cetrorelix (cetrotide) or ganirelix (orgulatron) 0.25mg) begins by subcutaneous administration every day till HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU). 36 h after HCG triggering, the mature oocytes are retrieved.	Drug: Human Chorionic Gonadotropin (hCG) Administration of hCG (10.000IU) for ovulation triggering Other Name: OVITRELLE / PREGNYL Drug: Gonadotropins Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day) Other Name: MENOPUR Drug: GnRH antagonist Administration of cetrorelix (cetrotide) or ganirelix (orgulatron) (0.25mg/day) Other Name: CETROTIDE / ORGULATRON
Active Comparator: Protocol "D" Long GnRH agonist protocol: For the long GnRH agonist protocol, a low dose of GnRH agonist (e.g., triptorelin (Decapeptyl 0.1mg)) is administered on cycle-day 21 followed by gonadotropin (e.g. Menopur, 150-225 IU) daily starting on cycle-day 2 after menses (Gonadotropin dose varies based on the follicular development). Continual administration of GnRH agonist and gonadotropin lasts until HCG triggering (e.g. Ovitrelle or Pregnyl, 10.000IU), ~14 days post GnRH agonist regimen when follicles size reached 16-18 mm. 36 h after HCG triggering, the mature oocytes are retrieved.	Drug: Human Chorionic Gonadotropin (hCG) Administration of hCG (10.000IU) for ovulation triggering Other Name: OVITRELLE / PREGNYL Drug: Gonadotropins Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day) Other Name: MENOPUR Drug: GNRH-A Triptorelin Administration of Triptorelin (0.1mg/day) Other Name: DECAPEPTYL
Active Comparator: Protocol "E" Combined GnRH antagonist and agonist protocol: For the combined protocol, it starts with the administration of gonadotropin (e.g. Menopur, 150-225 IU) daily which is initiated after monitoring of patients' follicles sizes on cycle-day 2/3 (Gonadotropin dose varies based on the follicular response). Almost after the 6th days of gonadotropin injection or when follicular size reaches more than or equal to 14 mm, GnRH antagonist (e.g., cetrorelix (cetrotide) or ganirelix (orgulatron) 0.25mg) begins by subcutaneous administration every day till GnRH agonist injection (e.g., triptorelin (Decapeptyl 0.1mg/day)). 36 h after agonist injection, the mature oocytes are retrieved.	Drug: Gonadotropins Administration of Menotropin (hMG / FSH and LH at a 1:1 ratio) (150-225IU/day) Other Name: MENOPUR Drug: GNRH-A Triptorelin Administration of Triptorelin (0.1mg/day) Other Name: DECAPEPTYL Drug: GnRH antagonist Administration of cetrorelix (cetrotide) or ganirelix (orgulatron) (0.25mg/day) Other Name: CETROTIDE / ORGULATRON

Outcome Measures

Primary Outcome Measures :

Ovulation Induction [ Time Frame: 36 hours ]
Monitoring of Ovulation Stimulation by trans-vaginal ultrasound determining the growth, number and appearance of the ovarian follicles as well as the maturation of the endometrium (measurement of its thickness); Follicles are considered mature when their diameter is greater than 18-20mm and each of them provides 250-300pg/mL of E2. When these criteria are obtained, ovulation is triggered

Secondary Outcome Measures :

fertilization rate [ Time Frame: 12 months ]
Changes in the fertilization rate
embryo quality [ Time Frame: 12 months ]
Selection of embryos for transfer depending on their morphology, and the regularity of blastomers
pregnancy rate [ Time Frame: 12 months ]
Determination of βHCG for positive results
live birth rate [ Time Frame: 12 months ]
Calculations of live birth rate are based on the number of live births in each group divided by all live births, multiplied by 100

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	21 Years to 44 Years (Adult)
Sexes Eligible for Study:	Female
Gender Based Eligibility:	Yes
Gender Eligibility Description:	The average age of the population must be around 30 years old. Note that no one of the 264 women in this study should have any chromosomal abnormalities or mutated genes that affect ovarian function.
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

must not show any of the excluded criteria
Patients affected by female infertility due to particularly Ovulatory Disorder, Premature Ovarian Failure, Polycystic Ovary Syndrome, Tubal Origin, Ectopic Pregnancy, Salpingitis, Tubal Block/Occlusion, Hydrosalpinx, Cervical/Vaginal, Endocrine, Endometriosis, Fibroids, Congenital Uterine Anomaly, Infections Uterine, and Female Infertility of Other Origin
The selection of subjects' age must be group matched between protocols of treatment. Premature ovarian failure is defined as AMH (Anti Mullerian Hormone) ≤ 2 ng/mL.
Willing to collaborate and to attend to the clinical follow-ups for the next three years
Patients willing to sign informed consent
Able and willing to comply with all study requirements
Absence of genetic causes
Medically suitable to undergo ovarian stimulation
Normal serum chemistry and hematology screening tests
Negative human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV) serology
No history of malignancy
Complete history & physical examination

Exclusion Criteria:

Subjects to be excluded from the study if the male (husband) had any male infertility problem(s)
Patients with any genetic abnormalities
Patients with histories of neurologic conditions including moderate or severe head injury, stroke, cerebral or bone damage or malignancies, brain abnormalities, learning disability, major medical or psychiatric illness, and metabolic/cardiovascular disease or evidence of cardiac/renal damage or malignancies, alcohol, loss of weight during the last 2 years, chemotherapy or immunosuppressive therapy.
Women aged 45 years and older, under 21 years

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04071574

Contacts

Layout table for location contacts

Contact: Nehman Makdissy, Professor	+96171210250	almakdissy@hotmail.com
Contact: Samar El Hamoui, Dr	+9613246315	simcima@ymail.com

Locations

Layout table for location information

Lebanon
Lebanese University, faculty of sciences III	Recruiting
Tripoli, North Lebanon, Lebanon, 961
Contact: Nehman Makdissy, Professor

Sponsors and Collaborators

Lebanese University

Investigators

Layout table for investigator information

Study Chair:	Nehman Makdissy, Professor	Lebanese University
Study Director:	Samar El Hamoui, Dr	Lebanese University

More Information

Layout table for additonal information

Responsible Party:	Nehman Makdissy, Professor, Lebanese University
ClinicalTrials.gov Identifier:	NCT04071574
Other Study ID Numbers:	LU-MC-001/18
First Posted:	August 28, 2019 Key Record Dates
Last Update Posted:	August 28, 2019
Last Verified:	August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Nehman Makdissy, Lebanese University:


Infertility; Ovarian; Ovulation; IVF; ICSI; Gonadotropin

Additional relevant MeSH terms:

Layout table for MeSH terms

Polycystic Ovary Syndrome Infertility Endometriosis Primary Ovarian Insufficiency Menopause, Premature Infertility, Female Pregnancy, Ectopic Salpingitis Ovarian Cysts Cysts Neoplasms Ovarian Diseases Adnexal Diseases Gonadal Disorders Endocrine System Diseases	Pregnancy Complications Fallopian Tube Diseases Pelvic Inflammatory Disease Triptorelin Pamoate Chorionic Gonadotropin Cetrorelix Prolactin Release-Inhibiting Factors Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Luteolytic Agents Contraceptive Agents, Female Contraceptive Agents Reproductive Control Agents Antineoplastic Agents, Hormonal

To Top